anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Ceritinib
Trial phase: Phase 2
ATC code: L01ED02 | L01XE28
SMILES: Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Participants who received LDK378 750mg once daily on a 28 day cycle.
Eligibility criteria:
Key Inclusion Criteria:

Histologically or cytologically confirmed diagnosis of Stage IIIb or IV NSCLC that carries an ALK rearrangement as determined locally by Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular Inc.) test.
Patients must have NSCLC that has progressed at study enrollment.
Patients must have received previous treatment with alectinib for treatment of locally advanced or metastatic NSCLC. Prior therapy with crizotinib as ALK inhibitor therapy in addition to alectinib is allowed. Alectinib doesn't need to be the last therapy prior to study enrollment. No particular sequence of prior alectinib and crizotinib is required for enrollment.
Patients must be chemotherapy-naïve or have received only one line of prior cytotoxic chemotherapy.
Age 18 years or older at the time of informed consent.

Key Exclusion Criteria:

Patients with known hypersensitivity to any of the excipients of LDK378.
Prior therapy with other ALK inhibitor investigational agents except crizotinib and alectinib.
Prior systemic anti-cancer (including investigational) therapy aside from alectinib, crizotinib and one regimen of previous cytotoxic chemotherapy for locally advanced or metastatic NSCLC.
Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms.
Patient with history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis.
Patients with history of carcinomatous meningitis.
Patient with a concurrent malignancy or history of a malignant disease other than NSCLC that has been diagnosed and/or required therapy within the past 3 years.
Patient has clinically significant, uncontrolled heart disease and/or recent cardiac event (within 6 months)
Intervention: Lurbinectedin
Trial phase: Phase 2
ATC code: L01XX69
SMILES: [H][C@@]12c3c(cc(C)c(OC)c3O)C[C@@H]([C@H](O)N3[C@H]4COC(=O)[C@]5(CS[C@H](c6c(OC(C)=O)c(C)c7c(c64)OCO7)[C@]31[H])NCCc1c5[nH]c3ccc(OC)cc13)N2C
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 39
Group description: lurbinectedin (PM01183) is presented as a lyophilized powder for concentrate for solution for infusion with strength of 4 mg / vial.

Lurbinectedin was administered at a dose of 3.2 mg/m² given as a 1-hour i.v. every three weeks (q3wk) (three weeks = one treatment cycle).
Eligibility criteria:
Inclusion Criteria:

Voluntarily signed and dated informed consent
Normal cardiac conduction and function (centrally read)
Blood pressure between 90 and 150 mmHg systolic, inclusive, and not higher than 90 mmHg diastolic.
Specific serum electrolyte levels

Exclusion Criteria:

Age > 65 years
Performance status = 2 [Eastern Cooperative Oncology Group (ECOG)]
Heart rhythm disturbances
Significant ischemic coronary disease, heart failure, myocardial infarction, or unstable angina within the last six months.
Prior exposure to anthracyclines at a cumulative dose of doxorubicin (or equivalent) > 450 mg/m²
Intervention: Lente
Trial phase: Phase 4
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(CC3C=NC=N3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC3C=NC=N3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)N3CCCC3C(=O)NC(CCCCN)C(=O)NC(C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C.[Zn]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 34
Group description: This is an open-label, randomized, two-way crossover study , one is IGlar/INPH treatment sequence and, another is INPH/IGlar sequence. Wherein, IGlar refers to glargine insulin and INPH refers to NPH insulin.

At the end of the study, all data acquired during the use of NPH insulin, regardless of the sequence were grouped as NPH.

NPH insulin: The same total daily NPH insulin dose was maintained for those randomized to INPH. All of them had pre-prandial Regular insulin (Humulin R™, Lilly, Brazil) switched to Lispro insulin (Humalog™, Lilly, Brazil), at the same dose as in use previously. . After 24 weeks, basal insulins were switched; in other words, individuals on NPH in the first period switched to glargine insulin, and the doses of pre-meal insulin were sustained.
Eligibility criteria:
Inclusion Criteria:

Patients with type 2 diabetes mellitus and chronic kidney disease secondary to diabetic nephropathy in stages 3 and 4 (moderate and severe nephropathy, corresponding to glomerular filtration rate of 15-59 ml/min/1.73m²) will be included in the study.

Exclusion Criteria:

Patients with systemic neoplasias,
HIV, chronic kidney disease or nephropathy from other etiologies,
severe psychiatric disorders
pregnant women.
Intervention: Cholecalciferol
Trial phase: Phase 2
ATC code: A11CC05 | A11CC55 | M05BB03 | M05BB04 | M05BB05 | M05BB07 | M05BB08 | M05BB09 | M05BX53
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)CCCC(C)C)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)CCC1=C
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 40
Group description: Vitamin D3 (cholecalciferol) - Single dose at enrolment of 10000 IU/kg of cholecalciferol (max 400000 IU)

Vitamin D3
Eligibility criteria:
Inclusion Criteria:

(i) Admitted to ICU; (ii) Corrected gestational age > 37 weeks to age < 18 years; (iii) Expected ICU admission in excess of 48 hours and expected access for blood work at Day 7 of hospital admission; (iv) Blood 25OHD less than 50 nmol/L (regardless of prior approach to supplementation)

Exclusion Criteria:

(i) Significant gastrointestinal disorder preventing enteral drug administration (e.g. necrotizing enterocolitis); (ii) Hypercalcemia (excluding transient abnormalities and those related to parenteral calcium administration for hypocalcemia); (iii) Confirmed or suspected William's syndrome; (iv) Patient known to have nephrolithiasis or Nephrocalcinosis; (v) Imminent plan for withdrawal of care or transfer to another ICU; (vi) Physician refusal; (vii) Previous enrollment in the study; (viii) Patient known to have granulomatous disease (tuberculosis or sarcoidosis), (ix) Severe liver dysfunction/liver failure; (x) Patient know to have hypersensitivity or allergy to vitamin D or any of the non-medicinal ingredients of the formulation; (xi) Patient on thiazide diuretics who is also receiving regular ongoing calcium supplementation above the daily recommended intake (for reasons other than hypocalcemia); (xii) Adolescent female of child-bearing age with a positive serum pregnancy test; or (xiii) Patient on digoxin-therapy
Intervention: Secnidazole
Trial phase: Phase 3
ATC code: J01RA07 | P01AB07
SMILES: Cc1ncc([N+](=O)[O-])n1CC(C)O
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 321
Group description: SYM-1219 2g single oral dose
Eligibility criteria:
Inclusion Criteria:

Are adult females or postmenarchal adolescent girls ≥ 12 years of age.
Are in good general health as confirmed by a medical history and physical examination, with no known medical or mental health conditions that, in the Investigator's opinion, may interfere with study participation.
Have a negative urine pregnancy test result prior to study treatment initiation. In addition, female patients of childbearing potential must be using an acceptable form of birth control as determined by the Investigator
Agree to abstain from alcohol for 3 days following study treatment.
Have a clinical diagnosis of bacterial vaginosis
Agree not to use vaginal douches or similar products for the duration of the study.

Exclusion Criteria:

Are pregnant, lactating, or planning to become pregnant during the study.
Are menstruating or have vaginal bleeding at the Baseline visit (Day 1).
Are menopausal as determined by the Investigator
Are suspected clinically (or confirmed diagnostically) of having alternative causes of vaginal symptoms including candidiasis, Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae or Herpes simplex
Have active genital lesions, including active Herpes simplex lesions, or other vaginal or vulvar conditions which could confound the interpretation of the clinical response, as determined by the Investigator
Have consumed any alcohol within 12 hours prior to treatment with study medication.
Have a history of an abnormal Pap smear which required cervical biopsy or cervical cauterization within 3 months of the Baseline visit (Day 1).
Have any history of cervical carcinoma or other carcinomas of the vagina or vulva.
Intervention: Leuprolide
Trial phase: Phase 3
ATC code: L02AE02 | L02AE51
SMILES: CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 64
Group description: Leuprolide acetate 45 mg will be administered as a subcutaneous injection at 6-month intervals for the 12 month study period.

Leuprolide Acetate 45 mg: Subcutaneous injection
Eligibility criteria:
Inclusion Criteria:

Females age 2 to 8 years (inclusive) or males age 2 to 9 years (inclusive)
Confirmed diagnosis of CPP within 12 months of Baseline Visit (Day 0) but have not received prior GnRH agonist treatment for CPP
Pubertal-type LH response following an abbreviated GnRHa stimulation test before treatment initiation
Clinical evidence of puberty, defined as Tanner stage ≥ 2 for breast development in females or testicular volume ≥ 4 mL in males
Difference between bone age (Greulich and Pyle method) and chronological age ≥ 1 year

Exclusion Criteria:

Gonadotropin-independent (peripheral) precocious puberty
Prior or current GnRH treatment for CPP
Prior or current therapy with medroxyprogesterone acetate, growth hormone or insulin-like growth factor-1 (IGF-1)
Diagnosis of short stature (ie, 2.25 standard deviations (SD) below the mean height for age)
Known history of seizures, epilepsy, and/or central nervous system disorders that may be associated with seizures or convulsions
Any other medical condition or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the subject to participate in the study
Intervention: Injectafer
Trial phase: Phase 3
SMILES: O.O=C([O-])C(O)C(O)C(OC1OC(CO)C(OC2OC(CO)C(OC3OC(CO)C(O)C(O)C3O)C(O)C2O)C(O)C1O)C(O)CO.[Fe+3].[O-2].[OH-]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 121
Group description: 2 doses of Injectafer at 15mg/kg for a maximum single dose of 750mg given 7 days apart for a total of up to 1500mg.

Injectafer
Eligibility criteria:
Inclusion Criteria:

Subjects (male of female) ≥ 18 years of age able to give informed consent to the study.
Subjects with non-myeloid malignancies
Receiving chemotherapy as part of their cancer treatment with at least 4 weeks of treatment remaining.
Screening visit central laboratory hemoglobin (Hgb) ≤11 g/dL, but ≥8 g/dL.
Ferritin between 100 and 800 ng/mL and transferrin saturation (TSAT) =<35%
Subjects must have Eastern Coopertative Oncology Group (ECOG) performance status of 0-2.
Life expectancy of at least 6 months.
Demonstrate the ability to understand the requirements of the study, willingness to abide by study restrictions and to return for the required assessments.

Exclusion Criteria:

Previous participation in a ferric carboxymaltose clinical trial.
Known hypersensitivity reaction to any component of ferric carboxymaltose.
Subjects with overt bleeding
Any anemia treatment within 4 weeks before inclusion (oral iron, IV iron, transfusion, or erythropoiesis-stimulating agents).
Subjects on erythropoiesis-stimulating agents.
Requiring dialysis for the treatment of chronic kidney disease.
Any non-viral infection.
Known positive hepatitis with evidence of active disease.
Received an investigational drug within 30 days of screening.
Alcohol or drug abuse within the past 6 months.
Hemochromatosis or other iron storage disorders.
Any other laboratory abnormality, medical condition or psychiatric disorders which in the opinion of the Investigator would put the subject's disease management at risk or may result in the subject being unable to comply with study requirements.
Pregnant or actively trying to become pregnant (Female subjects who are of childbearing age must have a negative pregnancy test at screening and be practicing an acceptable method of birth control during the study).
Intervention: Tozadenant
Trial phase: Phase 3
SMILES: COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 150
Group description: Part A (double-blind phase)

During Part A, patients took two (2) tablets, one 60 mg tozadenant and one placebo, by mouth BID for a total of four (4) tablets per day.
Eligibility criteria:
Inclusion Criteria:

Patient understands study requirements and has given his/her written informed consent on an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved consent form.
Parkinson's disease diagnosis consistent with UK Parkinson's Disease Society Brain Bank Diagnostic criteria
Minimum of 3 years since diagnosis.
Meet Hoehn and Yahr PD stage
Good response to levodopa
Stable regimen of anti-PD medications
Patients must have been taking a levodopa-containing anti-PD medication continuously for at least the previous 12 months
Patient has documented a minimum amount of Off time.
If of childbearing potential (male and female) must use an acceptable method of contraception

Exclusion Criteria:

Previous tozadenant study participation
Current or recent participation in another study.
Secondary or atypical parkinsonism
Neurosurgical intervention for PD
Patient is taking apomorphine, budipine, istradefylline, tolcapone, or DUOPA™/Duodopa®
Treatment with excluded medications
Untreated or uncontrolled hyperthyroidism or hypothyroidism
Clinically significant out-of-range laboratory
MMSE out of range
Current episode of major depression (stable treatment for depression is permitted).
Recent suicide attempt or suicidal ideation type 4 or type 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS)
Women lactating or pregnant
Hypersensitivity to any components of tozadenant or excipients
Abnormal findings on the physical or neurological examination, or medical history that would make the patient unsuitable for the study
History of hepatitis or cholangitis
Intervention: Tozadenant
Trial phase: Phase 3
SMILES: COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 149
Group description: Part A (double-blind phase)

During Part A, patients took two (2) tablets of 60 mg tozadenant, by mouth BID for a total of four (4) tablets per day.
Eligibility criteria:
Inclusion Criteria:

Patient understands study requirements and has given his/her written informed consent on an Institutional Review Board (IRB) or Independent Ethics Committee (IEC) approved consent form.
Parkinson's disease diagnosis consistent with UK Parkinson's Disease Society Brain Bank Diagnostic criteria
Minimum of 3 years since diagnosis.
Meet Hoehn and Yahr PD stage
Good response to levodopa
Stable regimen of anti-PD medications
Patients must have been taking a levodopa-containing anti-PD medication continuously for at least the previous 12 months
Patient has documented a minimum amount of Off time.
If of childbearing potential (male and female) must use an acceptable method of contraception

Exclusion Criteria:

Previous tozadenant study participation
Current or recent participation in another study.
Secondary or atypical parkinsonism
Neurosurgical intervention for PD
Patient is taking apomorphine, budipine, istradefylline, tolcapone, or DUOPA™/Duodopa®
Treatment with excluded medications
Untreated or uncontrolled hyperthyroidism or hypothyroidism
Clinically significant out-of-range laboratory
MMSE out of range
Current episode of major depression (stable treatment for depression is permitted).
Recent suicide attempt or suicidal ideation type 4 or type 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS)
Women lactating or pregnant
Hypersensitivity to any components of tozadenant or excipients
Abnormal findings on the physical or neurological examination, or medical history that would make the patient unsuitable for the study
History of hepatitis or cholangitis
Intervention: Netazepide
Trial phase: Phase 2
SMILES: CNc1cccc(NC(=O)N[C@@H]2N=C(c3ccccn3)c3ccccc3N(CC(=O)C(C)(C)C)C2=O)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: The dose will be an oral dose of 100 mg YF476 once daily. for 12 weeks. When 6 patients have completed 12 weeks' treatment with that dose, it may be increased to 150 or 200 mg once daily. Patients will have type II gastric carcinoids and/or ECL cell hyperplasia/dysplasia.

YF476: Gastrin receptor antagonist
Eligibility criteria:
Inclusion criteria:

Men; post-menopausal women; pre-menopausal women who have been sterilised by tubal ligation, hysterectomy or bilateral oophorectomy; or pre-menopausal women using one of the allowed methods of contraception: condom and spermicide or intra-uterine device.
Patients with serum gastrin >250 pg/mL.
Hepatic function: AST and ALT ≤2.0 x ULN; total bilirubin ≤1.0 x ULN.
Renal function: serum creatinine <1.0 x ULN.
Haematologic function: Hb ≥10.0 g/dL; WBC ≥3.5 x 10e9 /L; ANC ≥1.5 x 10e9 /L; platelets ≥100 x 10e9 /L.
Coagulation parameters: INR or PT ≤1.0 x ULN; PTT ≤1.0 x ULN.
Ability to communicate satisfactorily with the investigator and to participate in, and comply with the requirements of, the entire trial.
Willingness to give fully-informed, written consent.

Exclusion criteria:

Patients under 18 years.
Women who are pregnant, lactating or using a steroid contraceptive.
Prior gastric resection or bypass.
Planned gastrinoma resection during the study period.
Patients on somatostatin analogues, except for those on therapy for >6 months with stable or worsening carcinoids.
Inability to tolerate endoscopy, or refusal of endoscopy.
Physical findings, ECG (especially prolonged QTc interval >450 msec), or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the subject.
Certain medicines and herbal remedies taken during the 7 days before visit 2.
Participation in a trial of an IMP within the previous 28 days.
Presence of drug or alcohol abuse.

History or baseline findings of:

type 1 diabetes mellitus;
pancreatitis (baseline amylase and/or >2.0 x ULN);
hepatitis B, hepatitis C or HIV;
malabsorption syndrome or inability to swallow or retain oral medicine;
major surgery <28 days prior to enrolment;
ECOG performance status >2; or
another cancer within 3 years except for basal carcinoma of the skin or cervical carcinoma in-situ.
Also, any clinically significant and uncontrolled major morbidity including but not limited to; serious cardiac disease (unstable angina, s/p myocardial infarction <1 month); respiratory disease (advanced COPD or pulmonary fibrosis); uncontrolled hypertension; or active systemic infection.
Intervention: Fenofibrate
Trial phase: Phase 2 | Phase 3
ATC code: C10AB05 | C10BA03 | C10BA04 | C10BA09 | C10BA12
SMILES: CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Twenty subjects with adverse TG concentrations (i.e., paraplegia: >/=135 mg/dl; tetraplegia >/=115 mg/dl) will be randomized to receive once daily fenofibrate therapy (i.e., 145 mg) for 4 months

Fenofibrate: Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist that is demonstrated to reduce triglyceride concentrations in the blood.
Eligibility criteria:
Inclusion Criteria:

Male or female, age 21 to 69;
Chronic (e.g., duration of injury at least 6 months), stable SCI (regardless of level of neurological lesion);
American Spinal Injury Association Impairment Scale (AIS) designation of A, B or C; and
TG concentration 135 mg/dl (paraplegia) or 115 mg/dl (tetraplegia).

Exclusion Criteria:

Acute illness or infection;
Reduced kidney function (by glomerular filtration rate (GFR <60 ml/min) or liver function tests (LFTs 2.5 standard deviations above the upper limit of normal);
Current pharmacological treatment with: HMG-CoA reductase inhibitors (statins), or any other hypolipidemic agent; anti-coagulant therapy; cyclosporine; or any other medications known to effect the TG concentration (i.e., -blockers, thiazides or estrogen);
Hypersensitivity to fenofibrate;
Existing diagnosis of atherosclerosis, congestive heart failure, or recent history of myocardial infarction (i.e., 12 months);
Pregnancy or women who may become pregnant during the course of the study, or those who are nursing;
Diminished mental capacity; and
Inability or unwillingness of subject to provide informed consent.
Existing diagnosis of diabetes mellitus, or the results from screening blood tests indicate that diabetes mellitus is present (and perhaps undiagnosed); laboratory thresholds for exclusion will be as follows: HbA1C 6.5% and fasting plasma glucose is >126 mg/dl.
Intervention: Hydrocodone Bitartrate Acetaminophen
Trial phase: Phase 4
SMILES: CC(=O)Nc1ccc(O)cc1.COc1ccc2c3c1OC1C(=O)CCC4C(C2)N(C)CCC314.O=C(O)C(O)C(O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 416
Group description: Hydrocodone/acetaminophen (5 mg/300 mg)

Hydrocodone/acetaminophen
Eligibility criteria:
Inclusion Criteria:

Complaint of acute pain of < 7 days duration
Location of pain in one or more extremities defined as distal to and including the shoulder joint in the upper extremities and distal to and including the hip joint in the lower extremities;
Radiologic evaluation is planned

Exclusion Criteria:

Inability to confirm reliable means of phone followup.
Past use of methadone
Chronic condition requiring frequent pain management such as sickle cell disease, fibromyalgia, or any neuropathy
History of an adverse reaction to any of the study medications
Opioids taken in the past 24 hours
Ibuprofen or acetaminophen taken in past 8 hours
Pregnancy by either urine or serum HCG testing
Breastfeeding per patient report
History of peptic ulcer disease
Report of any prior use of recreational narcotics
Medical condition that might affect metabolism of opioid analgesics, acetaminophen, or ibuprofen such as hepatitis, renal insufficiency, hypo- or hyperthyroidism, Addison's or Cushing's disease
Taking any medicine that might interact with one of the study medications, such as antidepressant SSRI's or Tricyclics, antipsychotics, anti-malaria medications quinidine or halofantrine, Amiodarone or Dronedarone, diphenhydramine, celecoxib, ranitidine, cimetidine, ritanovir, terbinafine, or St John's Wort.